-200% increase in revenues in a $20B international market -Strong international patent suite to proprietary technology -Legit endorsement from medical and scientific community. They have Harvard Med School Professors on the advisory board -Technology that literally restores sight to the blind and makes inoperable brain procedures possible, 2000 medical procedures already performed - Market gaining momentum WITHOUT promo's. 14xs the average volume -Competition is largely non-existent -VBAS lauded in peer reviewed journals at Johns Hopkin's University, Cleveland Clinic, University of Illinois as technically superior - Over fifteen years of clinical research, it has been shown that in approximately 70% of cases patients using NovaVision's VRT system over a three to six month period experience significant recovery in at least one functional outcome. In many cases this recovery is enough to restore lost abilities such as reading, avoiding unseen objects while walking, or in some cases even driving a car.
Quote from Harbinger Research, which gave $VYCO it's highest investment rating:
"The Company Should Enter Hyper-growth During the Next Two to Three Years Vycor's ViewSite is already making good inroads into the relatively small neurosurgery market, both in the U.S. and overseas, and we expect sales to grow robustly beginning in early 2013. However, we are most excited about the long-term potential of the NovaVision subsidiary, as its products have no real competition and address a global market that could be up to $20B in size. Although NovaVision's products could require several years to achieve market penetration of even 5%, this would still equate to a huge win for a company of this size. Both NovaVision and ViewSite have strong patent protection and backing from the scientific community, and both are FDA 510(k) cleared for sale in the United States."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.